Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532

Michael C. Perry, Daniel C. Ihde, James E. Herndon, Michael L. Grossbard, Sara J. Grethein, James N. Atkins, Everett E. Vokes, Mark R. Green

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

In order to explore non-cisplatin containing regimens for advanced non- small cell lung cancer, Cancer and Leukemia Group B conducted a randomized Phase-II study of two novel combinations, paclitaxel/ifosfamide and vinorelbine/ifosfamide. Both regimens were active with a 38% response rate (95% CI: 24%, 53%) and 31% (95% CI: 18%, 47%), respectively. Median survivals were 8.5 and 7.4 months. Toxicity, mostly neutropenia, was acceptable. These two combinations establish a 'proof of principle' that non-cisplatin containing regimens also have activity in this setting. (C) 2000 Elsevier Science Ireland Ltd.

Original languageEnglish
Pages (from-to)63-68
Number of pages6
JournalLung Cancer
Volume28
Issue number1
DOIs
StatePublished - Apr 2000
Externally publishedYes

Keywords

  • Non-cisplatin containing regimens
  • Non-small cell lung cancer
  • Paclitaxel/ifosfamide
  • Vinorelbine/ifosfamide

Fingerprint

Dive into the research topics of 'Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532'. Together they form a unique fingerprint.

Cite this